Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes.

Journal Article (Journal Article;Review)

Glucagon is historically described as the counterregulatory hormone to insulin, induced by fasting/hypoglycemia to raise blood glucose through action mediated in the liver. However, it is becoming clear that the biology of glucagon is much more complex and extends beyond hepatic actions to exert control on glucose metabolism. We discuss the inconsistencies with the canonical view that glucagon is primarily a hyperglycemic agent driven by fasting/hypoglycemia and highlight the recent advances that have reshaped the metabolic role of glucagon. These concepts are placed within the context of both normal physiology and the pathophysiology of disease and then extended to discuss emerging strategies that incorporate glucagon agonism in the pharmacology of treating diabetes.

Full Text

Duke Authors

Cited Authors

  • Finan, B; Capozzi, ME; Campbell, JE

Published Date

  • April 2020

Published In

Volume / Issue

  • 69 / 4

Start / End Page

  • 532 - 541

PubMed ID

  • 31178432

Pubmed Central ID

  • PMC7085250

Electronic International Standard Serial Number (EISSN)

  • 1939-327X

Digital Object Identifier (DOI)

  • 10.2337/dbi19-0004


  • eng

Conference Location

  • United States